John Rhodes to Foramen Ovale, Patent
This is a "connection" page, showing publications John Rhodes has written about Foramen Ovale, Patent.
Connection Strength
1.086
-
Atrial fibrillation after closure of patent foramen ovale in the REDUCE clinical study. Catheter Cardiovasc Interv. 2022 04; 99(5):1551-1557.
Score: 0.198
-
Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke. JAMA Neurol. 2020 07 01; 77(7):878-886.
Score: 0.180
-
Comparison of Antiplatelet Therapies for Prevention of Patent Foramen Ovale-Associated Stroke. J Stroke Cerebrovasc Dis. 2020 Apr; 29(4):104632.
Score: 0.175
-
SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Catheter Cardiovasc Interv. 2019 04 01; 93(5):859-874.
Score: 0.165
-
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017 09 14; 377(11):1033-1042.
Score: 0.148
-
Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study. Int J Stroke. 2017 12; 12(9):998-1004.
Score: 0.143
-
Causes of recurrent focal neurologic events after transcatheter closure of patent foramen ovale with the CardioSEAL septal occluder. Am J Cardiol. 2008 May 15; 101(10):1487-92.
Score: 0.077